ObjectiveTo explore the teaching model of the "LungSmart" smart healthcare system in clinical pulmonology teaching and its effectiveness in enhancing the clinical reasoning skills of postgraduate students. MethodsA single-center, single-group pretest-posttest educational intervention study was conducted among 30 postgraduate students who participated in respiratory medicine-related teaching activities and enrolled in the "LungSmart" smart healthcare course at Shanghai Pulmonary Hospital from 2024 to 2025 academic year. The course was structured around three core components, namely an AI case repository, dynamic simulation, and immediate feedback, and was delivered over 16 weeks with a total of 64 class hours. Teaching effectiveness was assessed using pretest and posttest clinical reasoning ability scores, while students’ acceptance of the course was evaluated using a 5-point Likert questionnaire. ResultsAll 30 students completed the teaching activities and were included in the final analysis. The pretest score was (78.83±6.25) points, and the posttest score increased to (93.50±4.18) points, with a mean improvement of (14.67±7.06) points (95%CI, 12.03 to 17.30), indicating a statistically significant improvement after the intervention (t=11.37, P<0.001). A total of 30 valid questionnaires were collected at the end of the course, with a response rate of 100.0%. The overall satisfaction score was (4.67±0.15) points, and the mean scores for content satisfaction, practical value, interest stimulation, and professional competence were (4.72±0.23) points, (4.53±0.35) points, (4.72±0.39) points, and (4.75±0.43) points, respectively. ConclusionThese findings suggest that the clinical teaching model based on the "LungSmart" smart healthcare system is feasible and well accepted, and may help improve postgraduate students’ clinical reasoning ability.
Objective To summarize the research progress on the source and selection of donor cells in the field of islet replacement therapy for diabetes mellitus. Methods Domestic and abroad literature concerning islet replacement therapy for diabetes mellitus, as well as donor source and donor selection was reviewed and analyzed thoroughly. Results The shortage of donor supply is still a major obstacle for the widely clinical application of pancreatic islet transplantation (PIT). Currently, in addition to the progress on the allogeneic/autologous donor islet supply, some remarkable achievements have been also attained in the application of xenogeneic islet (from pig donor), as well as islet like cells derived from stem cells and islet cell line, potentially enlarging the source of implantable cells. Conclusion Adequate and suitable donor cell supply is an essential prerequisite for widely clinical application of PIT therapy for type 1 diabetes mellitus (T1DM). Further perfection of organ donation system, together with development of immune-tolerance induction, gene and bioengineering technology etc. will possibly solve the problem of donor cell shortage and provide a basis for clinical application of cellular replacement therapy for T1DM.
China is facing the double burden of high incidence of lung cancer and tuberculosis epidemic. Lung cancer combined with tuberculosis has a high incidence and complexity in clinical practice. High-risk groups include immunocompromised people, long-term smokers and people with a history of tuberculosis. The coexistence of the two diseases not only increases the difficulty of diagnosis and treatment decision-making, but also increases the risk of treatment-related adverse reactions and drug interactions. The guideline was developed by Committee of Integrated Rehabilitation for Lung Cancer, Chinese Anti-Cancer Association; Chinese and Western Integrated Lung Cancer Committee of Chinese Anti-Cancer Association; Society of Tuberculosis, Chinese Medical Association, aiming to standardize the diagnosis and treatment of lung cancer complicated with pulmonary tuberculosis. The guideline emphasizes the core position of combined diagnosis of multimodal imaging, etiology and pathology. It is proposed that anti-tuberculosis and anti-tumor treatment should be coordinated under the framework of multidisciplinary team, and drug interactions and timing optimization should be paid attention to. For surgical treatment, minimally invasive resection combined with systematic lymph node dissection is recommended after infection control. Systemic therapy requires individualized risk stratification and dynamic monitoring of efficacy and adverse reactions. Based on evidence-based medicine and Chinese clinical practice, combined with the accessibility of drugs and technologies, this guideline proposes a whole-process management pathway covering screening, diagnosis, treatment and follow-up, in order to improve the prognosis and quality of life of patients.